Healthcare on the GRAJ protocol. One fee. 195 countries. Join the protocol.
Healthcare buying is slower, more documented and more regulated than any other channel, and the reason is straightforward: the buyer is not the user, and the consequences of a bad product are not commercial. Everything about the sales cycle follows from that.
Whether a product is a medical device, a supplement, a cosmetic or general merchandise determines the entire regulatory path — and the classification is decided by claims and function, not by what you call it. A claim can move a product into a regulated class on its own.
Much institutional healthcare buying runs through GPOs that negotiate on behalf of many providers. Being on contract is the access; being off it usually means the individual hospital cannot buy from you even if they want to.
Long before price, procurement asks for evidence. Missing any of it stops the process regardless of the product.
Institutional buyers pay slowly and reliably. That is a financing problem rather than a credit problem, and it is exactly what receivables finance is for.